Hubbry Logo
CyanosisCyanosisMain
Open search
Cyanosis
Community hub
Cyanosis
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Cyanosis
Cyanosis
Cyanosis
View on Wikipedia
from Wikipedia
Cyanosis
Cyanosis of the hand of a patient with low oxygen saturations
SpecialtyPulmonology, cardiology
SymptomsHypothermia, numbness in the area where the cyanosis is, coughing, wheezing, difficulty breathing
TypesCircumoral, central, peripheral
CausesAirway problems, lung problems, heart problems, exposure to extreme cold
Differential diagnosisCircumoral cyanosis, peripheral cyanosis, central cyanosis
PreventionAvoid exposure to freezing cold temperatures, limit smoking or caffeine, avoid touching cyanide
MedicationAntidepressants, anti-hypertension medication, or if caused by other reasons, naloxone hydrochloride

Cyanosis is the change of tissue color to a bluish-purple hue, as a result of decrease in the amount of oxygen bound to the hemoglobin in the red blood cells of the capillary bed.[1] Cyanosis is apparent usually in the body tissues covered with thin skin, including the mucous membranes, lips, nail beds, and ear lobes.[1] Some medications may cause discoloration such as medications containing amiodarone or silver. Furthermore, mongolian spots, large birthmarks, and the consumption of food products with blue or purple dyes can also result in the bluish skin tissue discoloration and may be mistaken for cyanosis.[2][3] Appropriate physical examination and history taking is a crucial part to diagnose cyanosis. Management of cyanosis involves treating the main cause, as cyanosis is not a disease, but rather a symptom.[1]

Cyanosis is further classified into central cyanosis and peripheral cyanosis.

Pathophysiology

[edit]
Presentation of cyanosis varies depending on the color of the skin

The mechanism behind cyanosis is different depending on whether it is central or peripheral.

Central cyanosis

[edit]

Central cyanosis occurs due to decrease in arterial oxygen saturation (SaO2), and begins to show once the concentration of deoxyhemoglobin in the blood reaches a concentration of ≥ 5.0 g/dL (≥ 3.1 mmol/L or oxygen saturation of ≤ 85%).[4] This indicates a cardiopulmonary condition.[1]

Causes of central cyanosis are discussed below.

Peripheral cyanosis

[edit]

Peripheral cyanosis happens when there is increased concentration of deoxyhemoglobin on the venous side of the peripheral circulation. In other words, cyanosis is dependent on the concentration of deoxyhemoglobin. Patients with severe anemia may appear normal despite higher-than-normal concentrations of deoxyhemoglobin. While patients with increased amounts of red blood cells (e.g., polycythemia vera) can appear cyanotic even with lower concentrations of deoxyhemoglobin.[5][6]

A baby with a heart condition. Note purple nailbeds.

Causes

[edit]

Central cyanosis

[edit]

Central cyanosis is often due to a circulatory or ventilatory problem that leads to poor blood oxygenation in the lungs. It develops when arterial oxygen saturation drops below 85% or 75%.[5]

Acute cyanosis can be a result of asphyxiation or choking and is one of the definite signs that ventilation is being blocked.

Child with congenital heart disease with central cyanosis that is worsened by measles. Note the bluish-purple discoloration of the fingernails, lips, eyelids, and nose, along with prominent nail clubbing.

Central cyanosis may be due to the following causes:

  1. Central nervous system (impairing normal ventilation):[5]
  2. Respiratory system:[1][5]
  3. Cardiovascular system:[1][5]
  4. Hemoglobinopathies:[5]
  5. Others:
  1. ^ Note this causes "spurious" cyanosis, in that, since methemoglobin appears blue, the patient can appear cyanosed even in the presence of a normal arterial oxygen level.
  2. ^ Note a rare condition in which there is excess sulfhemoglobin (SulfHb) in the blood. The pigment is a greenish derivative of hemoglobin which cannot be converted back to normal, functional hemoglobin. It causes cyanosis even at low blood levels.

Peripheral cyanosis

[edit]

Peripheral cyanosis is the blue tint in fingers or extremities, due to an inadequate or obstructed circulation.[5] The blood reaching the extremities is not oxygen-rich and when viewed through the skin a combination of factors can lead to the appearance of a blue color. All factors contributing to central cyanosis can also cause peripheral symptoms to appear, but peripheral cyanosis can be observed in the absence of heart or lung failures.[5] Small blood vessels may be restricted and can be treated by increasing the normal oxygenation level of the blood.[5]

Initial direction of blood flow in patients with patent ductus arteriosus. Once the pressure of the pulmonary arteries increases more than the aorta due to right heart hypertrophy, the direction of blood flow reverses, sending deoxygenated blood through the patent duct directly into the descending aorta while sparing the brachiocephalic trunk, left common carotid, and left subclavian artery, therefore causing the differential cyanosis.

Peripheral cyanosis may be due to the following causes:[5]

Differential cyanosis

[edit]
This illustration depicts a self-induced local (tissue) hypoxia on the right hand (right side of the picture) versus a normal left hand (left side of the picture). The cyanosis was achieved by inflating and tightening the blood pressure cuff on the right arm.

Differential cyanosis is the bluish coloration of the lower but not the upper extremity and the head.[5] This is seen in patients with a patent ductus arteriosus.[5] Patients with a large ductus develop progressive pulmonary vascular disease, and pressure overload of the right ventricle occurs.[8] As soon as pulmonary pressure exceeds aortic pressure, shunt reversal (right-to-left shunt) occurs.[8] The upper extremity remains pink because deoxygenated blood flows through the patent duct and directly into the descending aorta while sparing the brachiocephalic trunk, left common carotid, and left subclavian arteries.

Evaluation

[edit]

A detailed history and physical examination (particularly focusing on the cardiopulmonary system) can guide further management and help determine the medical tests to be performed.[1] Tests that can be performed include pulse oximetry, arterial blood gas, complete blood count, methemoglobin level, electrocardiogram, echocardiogram, X-Ray, CT scan, cardiac catheterization, and hemoglobin electrophoresis.

In newborns, peripheral cyanosis typically presents in the distal extremities, circumoral, and periorbital areas.[9] Of note, mucous membranes remain pink in peripheral cyanosis as compared to central cyanosis where the mucous membranes are cyanotic.[9]

An example of cyanosis in an individual with darker skin pigmentation. Note the pale purple (instead of the typical bluish-purple hue) nail beds. This patient also had prominent digital clubbing due to a congenital heart disease with right-to-left shunting (this patient had Tetralogy of Fallot).

Skin pigmentation and hemoglobin concentration can affect the evaluation of cyanosis. Cyanosis may be more difficult to detect on people with darker skin pigmentation. However, cyanosis can still be diagnosed with careful examination of the typical body areas such as nail beds, tongue, and mucous membranes where the skin is thinner and more vascular.[1] As mentioned above, patients with severe anemia may appear normal despite higher than normal concentrations of deoxyhemoglobin.[5][6] Signs of severe anemia may include pale mucosa (lips, eyelids, and gums), fatigue, lightheadedness, and irregular heartbeats.

An example of cyanosis in an elderly individual with darker skin pigmentation. Note the dark purple hue of the lips.

Management

[edit]

Cyanosis is a symptom, not a disease itself, so management should be focused on treating the underlying cause.

If it is an emergency, management should always begin with securing the airway, breathing, and circulation. In patients with significant respiratory distress, supplemental oxygen (in the form of nasal canula or continuous positive airway pressure depending on severity) should be given immediately.[10][11]

If the methemoglobin levels are positive for methemoglobinemia, first-line treatment is to administer methylene blue.[1]

History

[edit]

The name cyanosis literally means the blue disease or the blue condition. It is derived from the color cyan, which comes from cyanós (κυανός), the Greek word for blue.[12]

It is postulated by Dr. Christen Lundsgaard that cyanosis was first described in 1749 by Jean-Baptiste de Sénac, a French physician who served King Louis XV.[13] De Sénac concluded from an autopsy that cyanosis was caused by a heart defect that led to the mixture of arterial and venous blood circulation. But it was not until 1919, when Dr. Lundsgaard was able to derive the concentration of deoxyhemoglobin (8 volumes per cent) that could cause cyanosis.[13]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Cyanosis

View on Grokipedia
from Grokipedia
Cyanosis is a bluish discoloration of the skin, lips, and mucous membranes caused by an increased concentration of deoxygenated in the blood, typically exceeding 5 g/dL, which reflects inadequate tissue oxygenation. This condition serves as a clinical sign of underlying rather than a itself, arising from mechanisms such as reduced arterial oxygen tension, increased oxygen extraction by tissues, or circulatory stasis. It becomes visible when arterial falls below approximately 80-85%, though visibility can vary based on pigmentation, lighting conditions, and levels. Cyanosis is classified into two primary types: central cyanosis, which affects the entire body including mucous membranes due to systemic from pulmonary, cardiac, or hemoglobin-related causes; and peripheral cyanosis, which is localized to the extremities and results from local or reduced peripheral blood flow without central . Central cyanosis often presents with generalized bluish discoloration of the , , and nail beds, sometimes accompanied by digital clubbing in chronic cases, while peripheral cyanosis manifests as cool, blue extremities with delayed but spares the central mucous membranes. Differential features include the absence of dyspnea in peripheral forms and potential asymmetry in certain cardiac conditions. Common causes of cyanosis include respiratory disorders such as (COPD), , or ; congenital heart defects like that mix oxygenated and deoxygenated blood; hemoglobinopathies including ; and environmental factors like high altitude or cold exposure leading to peripheral . Additional etiologies encompass reduced , vascular obstructions, or abnormal pigments like sulfhemoglobin, which can mimic true . In newborns, cyanosis may signal critical congenital heart disease, often presenting with feeding difficulties, , or growth failure alongside the bluish hue. Diagnosis involves clinical observation, to assess , arterial blood gas analysis to confirm , and targeted imaging such as chest X-rays or to identify underlying . Management focuses on treating the root cause, including supplemental oxygen for , warming and vasodilators for peripheral cases, or specific interventions like for congenital defects and for . Early recognition is crucial, as untreated cyanosis can lead to severe complications like organ hypoxia or developmental delays in infants.

Pathophysiology

Oxygen Desaturation Mechanisms

Cyanosis manifests as a bluish discoloration of the skin, , , or mucous membranes, resulting from an absolute concentration of reduced (deoxygenated) exceeding 5 g/dL in the . This threshold represents the point at which the accumulation of deoxygenated becomes visually apparent, independent of the overall percentage. In normal , is predominantly oxyhemoglobin, which imparts a red hue due to its absorption ; however, when deoxygenated predominates in capillaries, it alters interaction, leading to the characteristic blue tint. The blue coloration arises from the differential absorption of light by deoxygenated , which strongly absorbs longer wavelengths (red light, 600-700 nm) while transmitting shorter wavelengths (blue light, 400-500 nm). This selective absorption reduces red reflectance from the skin, allowing blue light—scattered by in the dermal layers—to dominate the perceived color, creating a purple-blue appearance rather than true blue blood. preferentially disperses shorter wavelengths in tissues, enhancing visibility of the deoxygenated state. Cyanosis is classified as absolute when the total deoxygenated surpasses 5 g/dL, irrespective of total hemoglobin levels, or relative when visibility is modulated by baseline concentration, such as in . In anemic patients with below 5 g/dL, even complete desaturation may not produce visible cyanosis due to insufficient absolute deoxygenated . Visibility is further influenced by factors including thickness, pigmentation, and ambient lighting, with discoloration most evident in areas with thin like the or nail beds. Arterial oxygen content, which underscores desaturation's impact, is calculated as: CaO2=(1.34×Hb×SaO2)+(0.0031×PaO2)\text{CaO}_2 = (1.34 \times \text{Hb} \times \text{SaO}_2) + (0.0031 \times \text{PaO}_2) where Hb is hemoglobin concentration (g/dL), SaO₂ is arterial oxygen saturation (as a decimal fraction, e.g., 0.95 for 95%), and PaO₂ is partial pressure of oxygen (mmHg); low SaO₂ directly reduces CaO₂, promoting deoxygenated hemoglobin accumulation. At the tissue level, cyanosis reflects hypoxia from impaired oxygen delivery, encompassing diffusion limitations across membranes, reduced perfusion (stagnant hypoxia), or defective cellular utilization (histotoxic hypoxia). These mechanisms collectively lower tissue oxygenation, exacerbating deoxygenation in capillaries.

Central and Peripheral Distinctions

Cyanosis is classified into central and peripheral types based on the distribution of bluish discoloration and the underlying circulatory mechanisms. Central cyanosis manifests as a generalized bluish tint affecting the skin, , , and other mucous membranes across the entire body, resulting from systemic arterial where arterial (SaO2) falls below approximately 85%. In contrast, peripheral cyanosis is localized to the distal extremities, such as the fingers, toes, nail beds, , and sometimes the ears or , while sparing the central mucous membranes, and arises from local circulatory disturbances rather than global oxygen deficiency. The pathophysiologic differences between these types stem from distinct alterations in oxygen delivery and extraction. Central cyanosis occurs due to reduced partial pressure of arterial oxygen (PaO2), often from right-to-left shunting of deoxygenated blood or ventilation-perfusion (V/Q) mismatch, leading to elevated levels of deoxyhemoglobin exceeding 5 g/dL systemically. Peripheral cyanosis, however, involves normal arterial oxygenation but increased oxygen extraction in the peripheral tissues, caused by stasis in capillaries and venules, low cardiac output, vasoconstriction, or venous obstruction, which slows blood flow and promotes deoxygenation locally. Central cyanosis typically has a more rapid onset, reflecting acute systemic hypoxemia, and may be reversible with supplemental oxygen if the underlying issue is pulmonary in nature, whereas peripheral cyanosis develops more gradually and shows a poor response to oxygen therapy, improving instead with measures to enhance peripheral perfusion, such as warming. A rare variant known as differential cyanosis presents with asymmetrical distribution, where the upper body remains pink while the lower body exhibits bluish discoloration, commonly due to reversed flow through a in the presence of , allowing oxygenated blood to preferentially supply the upper extremities. Reverse differential cyanosis, conversely, features cyanosis predominantly in the upper body with relative sparing of the lower extremities, as seen in transposition of the great arteries with and conditions like aortic coarctation or interrupted , where deoxygenated blood is shunted to the head and arms. Acrocyanosis represents a benign form of peripheral cyanosis, characterized by transient bluish discoloration of the hands, feet, and sometimes the perioral area, often observed in newborns or during cold exposure, without evidence of true arterial or systemic involvement. Unlike peripheral cyanosis, stems from physiologic and resolves spontaneously, typically within days in infants, and does not require intervention unless associated with underlying circulatory compromise.

Causes

Cardiac and Pulmonary Causes

Cardiac causes of central cyanosis primarily arise from congenital heart diseases that result in right-to-left shunting, where deoxygenated blood bypasses the lungs and enters the systemic circulation directly. Common examples include , characterized by pulmonary stenosis, , , and , leading to reduced pulmonary blood flow and shunting through the septal defect. Another key condition is transposition of the great arteries, where the aorta arises from the right ventricle and the pulmonary artery from the left, causing parallel circulations that mix only via septal or ductal communications, resulting in profound shortly after birth. In adults, develops from uncorrected congenital defects, such as ventricular septal defects, leading to that reverses the shunt direction from left-to-right to right-to-left, exacerbating cyanosis. These cardiac mechanisms typically produce arterial oxygen partial pressure (PaO2) levels below 60 mmHg, reflecting significant systemic desaturation due to the shunted blood. Cyanotic congenital heart diseases represent approximately 25% of all congenital heart defects, which have an overall birth prevalence of 8-9 per 1000 live births. Pulmonary causes of central cyanosis stem from conditions that impair , such as ventilation-perfusion (V/Q) mismatch, diffusion limitations, or , leading to widespread . Severe exacerbations of or (COPD) cause and airway obstruction, resulting in uneven ventilation and V/Q imbalance that lowers overall oxygen uptake. Infections like disrupt alveolar function through consolidation and inflammation, while obstructs pulmonary arteries, creating dead space and shunting-like effects. exemplifies diffusion impairment, where thickened alveolar walls hinder oxygen transfer from air to blood. , often seen in unacclimatized individuals ascending rapidly above 2500 meters, involves non-cardiogenic from hypoxic pulmonary , leading to patchy V/Q mismatch and acute . In pulmonary disorders, PaO2 often falls below 60 mmHg during acute , contributing to visible central cyanosis, particularly in advanced chronic diseases prevalent among adults. Chronic conditions like COPD are a leading cause of central cyanosis in adult populations, especially in severe stages with persistent .

Hematologic and Circulatory Causes

Hematologic causes of cyanosis primarily involve abnormalities in structure or function that impair oxygen transport or alter blood color, leading to a bluish discoloration despite adequate oxygenation in some cases. Methemoglobinemia, a condition where is oxidized to (metHb), which cannot bind oxygen effectively, is a key hematologic . Acquired forms arise from exposure to oxidizing agents such as nitrates, nitrites, or drugs like dapsone and , while congenital cases result from deficiencies in enzymes like b5 reductase. Cyanosis becomes clinically apparent when metHb levels exceed 1.5 g/dL (approximately 10-20% of total hemoglobin), producing characteristic chocolate-brown blood and a slate-gray tint unresponsive to supplemental oxygen. Sulfhemoglobinemia, a rarer dyshemoglobinemia, occurs when sulfur binds to , forming that also impairs oxygen delivery. It is typically acquired through medications like phenazopyridine or dapsone, or from increased intestinal sulfur-producing bacteria, and induces cyanosis at lower concentrations (as little as 0.5 g/dL) compared to , with normal arterial oxygen tension. Patients often present with mild cyanosis and low readings without significant respiratory distress. Certain hemoglobinopathies, such as hemoglobin M (Hb M) variants, cause congenital methemoglobinemia by stabilizing the ferric form of heme, leading to lifelong cyanosis from birth. Examples include Hb M-Iwate and Hb M-Hyde Park, where amino acid substitutions in alpha or beta chains promote metHb formation, resulting in persistent slate-blue discoloration without hypoxemia. These variants are inherited autosomally and typically cause asymptomatic or mildly symptomatic cyanosis. Circulatory causes of cyanosis stem from impaired blood flow or distribution, increasing oxygen extraction in peripheral tissues or altering the visibility of deoxygenated . Peripheral cyanosis arises from reduced or stasis in the extremities, often due to or low-flow states. Raynaud's phenomenon, characterized by episodic triggered by cold or stress, slows blood flow and enhances oxygen unloading, producing in fingers and toes. Shock, through systemic and compensatory , shunts blood away from the skin, leading to cool, blue extremities as deoxygenated accumulates. Low-output states, such as those in decompensated , similarly diminish peripheral delivery of oxygenated blood, exacerbating local desaturation. In central circulatory contexts, severe can paradoxically mask cyanosis by reducing total levels, requiring profound desaturation (often >50%) to reach the 5 g/dL threshold of deoxygenated needed for visible bluish tint. Conversely, increases concentration, making cyanosis more prominent even at moderate desaturation levels due to higher absolute amounts of deoxygenated and potential hyperviscosity effects on flow. Toxic exposures can induce cyanosis through mechanisms disrupting oxygen utilization or hemoglobin function. Drugs like dapsone contribute via acquired , as noted earlier. Pseudocyanosis, a non-hypoxic mimic, includes from chronic silver deposition, which imparts a permanent skin discoloration without affecting oxygen transport. This rare condition results from colloidal silver ingestion or occupational exposure and is distinguished by its irreversibility and lack of associated .

Clinical Presentation

Signs and Symptoms

Cyanosis manifests primarily as a bluish or purplish discoloration of the and mucous membranes due to inadequate oxygenation of the blood. This visible sign is most apparent in areas with thin or high , such as the , , , nail beds, ears, and conjunctivae. In healthy individuals, nail beds exhibit a uniform pink color with a glossy appearance, and the color returns within less than 2 seconds after blanching by pressing, indicating normal perfusion. In individuals with darker tones, the discoloration may appear grayish rather than blue and is often more noticeable on the palms, soles, or mucous membranes. Central cyanosis presents with a generalized tint affecting the entire body, particularly prominent in the mucous membranes and worse under conditions of low . Associated symptoms include (dyspnea), , rapid heart rate (), and a sensation of air hunger (). In severe cases, patients may exhibit altered mental status, such as or drowsiness, alongside widespread involvement of the trunk and extremities. In older adults, blue or purple discoloration of the lips is a common manifestation of central cyanosis. This finding frequently indicates underlying cardiopulmonary conditions, such as chronic obstructive pulmonary disease (COPD), heart failure, pneumonia, or poor peripheral circulation. The presence of accompanying symptoms such as shortness of breath, confusion, or chest pain typically warrants prompt medical evaluation. Peripheral cyanosis, in contrast, is limited to an acral distribution involving the fingers, toes, hands, feet, and earlobes, often with cold extremities due to . Accompanying complaints typically include pain, numbness, or tingling from reduced peripheral , without prominent respiratory distress. The mucous membranes remain pink in this form, distinguishing it from central involvement. In pediatric cases, such as in a 4-year-old child, perioral cyanosis—characterized by bluish discoloration around the mouth—may present as a variant of peripheral cyanosis due to temporary and relatively harmless factors like hypothermia, prolonged crying, physical exertion, or exposure to cold, which typically resolves quickly after warming or calming. However, perioral cyanosis can also indicate serious central hypoxemia from conditions such as respiratory problems (e.g., asthma, pneumonia, bronchiolitis), congenital heart defects, or dehydration affecting blood oxygenation, necessitating prompt evaluation. In chronic cyanosis, digital clubbing—enlargement and rounding of the fingertips—may develop as an adaptive response. Severity is gauged by the extent of discoloration: mild cases may affect only the or nail beds, while severe presentations involve the entire body and are accompanied by systemic symptoms like or limpness, especially in children. In neonates, cyanosis accompanied by indicates the need for urgent evaluation. A key non-visual indicator is a reading (SpO2) below 90%, which often serves as an initial alert for in cyanotic presentations. Central and peripheral forms differ in their distribution and response to interventions like warming, with central cyanosis persisting despite such measures.

Differential Features

True cyanosis is characterized by a bluish discoloration of the skin and mucous membranes due to the presence of at least 5 g/dL of deoxygenated in the capillaries, resulting from or circulatory issues. In contrast, pseudocyanosis mimics this appearance without underlying hypoxia or increased deoxygenated , often caused by exogenous factors such as ingestion of certain drugs (e.g., ) or exposure to metals (e.g., silver in ), leading to a tint with normal on or gas analysis. Pallor, or paleness of the skin, differs from as it lacks the characteristic blue hue and typically arises from or , where low levels (e.g., <9 g/dL) prevent sufficient deoxygenated accumulation to produce cyanosis even in the presence of hypoxemia; pallor often improves with warming in cases of . Duskiness observed in shock, often mottled and irregular, represents peripheral hypoperfusion rather than uniform bluish discoloration, sparing central mucous membranes and typically resolving with fluid resuscitation to restore circulation. Location provides a key differential feature: central cyanosis appears uniformly across the body, including warm mucous membranes like the lips and tongue, indicating systemic hypoxemia, whereas peripheral cyanosis is confined to distal extremities such as fingers and toes in cooler, poorly perfused areas, and is absent in well-perfused, warm regions. Reversibility testing further aids differentiation; peripheral cyanosis often improves with local warming or massage to enhance blood flow, while central cyanosis may partially resolve with administration of 100% oxygen if due to ventilation-perfusion mismatch but persists in cases of right-to-left shunting or hemoglobinopathies. Conditions like jaundice, presenting with a yellowish tinge rather than blue, can be distinguished by the hue difference and confirmed via serum bilirubin levels, without associated hypoxemia.

Diagnosis

History and Physical Examination

The evaluation of cyanosis begins with a thorough history to identify potential etiologies and guide the physical examination. Key elements include the onset of symptoms, which may be acute (suggesting acquired causes such as pneumonia or pulmonary embolism) or chronic (indicating congenital conditions like tetralogy of Fallot or chronic obstructive pulmonary disease). Exposures to environmental factors like high altitude or cold temperatures, as well as drugs (e.g., nitrates or dapsone leading to methemoglobinemia), should be explored, as they can precipitate peripheral or central cyanosis. Comorbidities such as preexisting heart or lung disease (e.g., heart failure or chronic lung conditions) and family history of congenital anomalies or hemoglobinopathies are critical to ascertain, as they point toward hereditary or structural causes. In neonates and infants, the history should encompass birth details (e.g., gestational age, delivery complications, Apgar scores) and feeding issues, such as intolerance or poor weight gain, which may signal underlying congenital heart defects. The physical examination focuses on non-invasive assessment to differentiate central from peripheral cyanosis and detect associated findings. Inspection begins with evaluating the distribution of bluish discoloration under natural or adequate lighting (e.g., daylight or tungsten bulbs at less than 20 footcandles to enhance visibility), targeting sites with minimal pigmentation and superficial capillary beds such as the lips, tongue, oral mucosa, nail beds, ears, and conjunctiva; the tongue is the most sensitive site, while lips provide specificity for central involvement. Central cyanosis affects mucous membranes and is accompanied by warm extremities, whereas peripheral cyanosis is limited to acral areas like hands and feet with cold peripheries. Palpation assesses peripheral pulses (e.g., brachial and femoral for symmetry and strength), temperature gradients (cooler in peripheral cyanosis), and capillary refill time by nail bed blanching; in healthy individuals, the nail bed is uniformly pink with a glossy appearance and color returns to pink within less than 2 seconds after pressing, whereas prolongation beyond 2 seconds supports peripheral involvement due to poor perfusion. Auscultation of the lungs may reveal crackles, wheezes, or diminished breath sounds indicating respiratory pathology, while cardiac evaluation listens for murmurs, gallops, or asymmetry suggestive of congenital or acquired heart disease; additional signs like digital clubbing (indicating chronic hypoxemia) or peripheral edema (from right heart failure) should be noted. Bedside tests complement the exam, including simple maneuvers like assessing tongue and lip color under natural light to confirm central cyanosis without reliance on instrumentation. In neonates, rapid inspection for nasal flaring, intercostal retractions, or grunting respirations during examination helps gauge severity. Red flags warranting urgent intervention include sudden onset cyanosis accompanied by chest pain or dyspnea, raising concern for pulmonary embolism, and feeding intolerance or respiratory distress in infants, which may indicate critical congenital heart disease. These findings necessitate prompt stabilization and further diagnostic pursuit.

Laboratory and Imaging Tests

Laboratory tests play a crucial role in confirming cyanosis, quantifying oxygenation levels, and identifying underlying etiologies such as or dyshemoglobinemias. Arterial blood gas (ABG) analysis is essential, measuring partial pressure of oxygen (PaO2) to assess hypoxemia (typically <80 mmHg in cyanotic conditions), oxygen saturation (SaO2), and pH to evaluate acid-base status, which can indicate respiratory or metabolic compensation. Co-oximetry, a specialized form of spectrophotometry, is used to detect abnormal hemoglobin species, particularly elevated methemoglobin levels (>10% or >1.5 g/dL can cause cyanosis), as it differentiates these from oxyhemoglobin more accurately than standard . (CBC) helps identify hematologic contributors, such as (reducing oxygen-carrying capacity) or (a compensatory response in chronic hypoxemia). B-type (BNP) levels are measured to evaluate for , where elevations (>100 pg/mL) suggest cardiac strain contributing to central cyanosis. Pulse oximetry serves as a non-invasive screening tool for initial assessment, with readings below 85-90% supporting cyanosis, though it overestimates saturation in dyshemoglobinemias like due to its reliance on two wavelengths. The , involving administration of 100% oxygen (FiO2 1.0) and subsequent ABG, is particularly useful in neonates or suspected cardiac shunts; a PaO2 >150 mmHg effectively rules out right-to-left shunting, as persistent indicates fixed intracardiac or intrapulmonary defects. Imaging modalities provide structural insights into cyanosis causes. Chest X-ray is a first-line test to detect pulmonary pathologies like , , or contributing to ventilation-perfusion mismatch. Echocardiography, including transthoracic and transesophageal approaches, is indispensable for visualizing cardiac shunts, valvular abnormalities, or , with Doppler imaging quantifying shunt severity. Computed tomography (CT) or (MRI) is employed for suspected , vascular anomalies, or complex congenital heart disease, offering detailed vascular mapping without radiation in MRI. Advanced investigations target specific etiologies. Ventilation-perfusion (V/Q) scanning assesses pulmonary thromboembolism or mismatched perfusion, showing characteristic segmental defects in conditions like chronic thromboembolic pulmonary hypertension. Genetic testing, such as sequencing of the CYB5R3 gene, confirms congenital methemoglobinemia in persistent cases unresponsive to oxygen therapy.

Management

Acute Interventions

The initial management of acute cyanosis prioritizes stabilization of the airway, breathing, and circulation (ABCs) to address life-threatening hypoxemia or hypoperfusion. Airway patency must be ensured immediately, with intubation and mechanical ventilation considered if the patient exhibits hypoventilation, severe respiratory distress, or obtundation. Oxygen supplementation is administered via nasal cannula, face mask, or high-flow systems, targeting a peripheral oxygen saturation (SpO2) of 94-98% in cases without right-to-left shunting or hypercapnia risk to optimize oxygenation while minimizing risks of hyperoxia. In shunt-dependent conditions, such as certain congenital heart diseases, lower targets around 80-85% may be appropriate to avoid excessive pulmonary blood flow from hyperoxia-induced vasodilation. Patient positioning plays a key role in acute interventions tailored to the underlying mechanism. For cyanosis associated with , an upright position is recommended to reduce venous return and alleviate respiratory distress. Conversely, in suspected right contributing to central cyanosis, fluid administration should be minimized or avoided to prevent exacerbation of congestion, with cautious use of diuretics if overload is evident. Specific therapies address etiology-driven causes in cyanotic emergencies. For methemoglobinemia-induced cyanosis, intravenous is given at 1-2 mg/kg over 3-5 minutes, with repeat dosing if levels remain elevated after 30-60 minutes, particularly in symptomatic patients or those with levels ≥20%. In peripheral cyanosis due to shock from hypoperfusion, vasopressors such as norepinephrine are initiated to maintain above 65 mmHg, thereby improving tissue , though extravasation risks must be monitored. Continuous monitoring is essential during acute interventions, including pulse oximetry for real-time SpO2 assessment and electrocardiography to detect arrhythmias that may worsen hypoxemia. Patients with persistent arterial partial pressure of oxygen (PaO2) below 50 mmHg despite initial therapy require urgent transfer to an intensive care unit for advanced support.

Underlying Cause Treatment

Treatment of the underlying cause of cyanosis is directed at addressing the specific etiology to improve oxygenation and resolve the bluish discoloration. For cardiac causes, such as cyanotic congenital heart defects, definitive management often involves surgical repair to correct anatomical abnormalities and restore normal blood flow. In tetralogy of Fallot, a palliative modified Blalock-Taussig shunt may be performed initially to increase pulmonary blood flow, typically followed by complete intracardiac repair. For duct-dependent lesions, where systemic or pulmonary circulation relies on a patent ductus arteriosus, continuous infusion of prostaglandin E1 (alprostadil) is administered to maintain ductal patency until surgical intervention can be undertaken, starting at low doses such as 0.01 μg/kg/min to minimize side effects like apnea. Pulmonary causes of cyanosis require targeted therapies to enhance ventilation and . In cases of severe exacerbations contributing to and cyanosis, short-acting beta-2 agonists like albuterol serve as first-line bronchodilators to rapidly relieve airflow obstruction, often combined with systemic corticosteroids such as (40-60 mg daily) to reduce and prevent relapse. For , anticoagulation with direct oral agents like or is the cornerstone of therapy to prevent clot propagation and recurrence, initiated after hemodynamic stabilization. In (COPD) with persistent leading to cyanosis, long-term is recommended for patients with resting PaO2 ≤ 55 mmHg or ≤ 88%, delivered via to improve survival and quality of life. Hematologic etiologies demand specific interventions to correct abnormal hemoglobin states. Methemoglobinemia, characterized by elevated methemoglobin levels causing cyanosis, can be treated with ascorbic acid (1 g intravenously every 4-6 hours) as an adjunctive or alternative therapy, particularly when methylene blue is contraindicated, to reduce methemoglobin through non-enzymatic means. In severe or refractory cases, exchange transfusion is employed to rapidly remove methemoglobin-laden red blood cells and replace them with normal erythrocytes. For glucose-6-phosphate dehydrogenase (G6PD) deficiency, which predisposes to oxidative hemolysis and cyanosis upon oxidant exposure, primary management focuses on avoidance of triggering agents such as certain antimalarials (e.g., primaquine), sulfonamides, and fava beans to prevent acute episodes. Supportive measures address peripheral and circulatory aspects of cyanosis. Peripheral cyanosis due to from cold exposure or low responds to gentle warming of the affected areas and to promote and improve peripheral . Vasodilators, such as (e.g., ), may be used in conditions like Raynaud's phenomenon contributing to peripheral cyanosis to reduce vasospastic episodes. In secondary associated with chronic cyanosis, such as in longstanding cyanotic heart disease, therapeutic is indicated for symptomatic hyperviscosity ( >65%) to reduce blood and alleviate symptoms, with careful monitoring to avoid .

Special Considerations

Neonatal and Pediatric Aspects

Cyanosis in neonates often presents as a transient phenomenon shortly after birth, commonly resulting from birth or delayed transition from fetal to neonatal circulation, and typically resolves within hours with appropriate stimulation or supportive care. Persistent neonatal cyanosis, however, signals more serious underlying pathology, most frequently congenital heart disease (CHD), which affects approximately 1% of live births, with cyanotic lesions accounting for about 25% of cases. Other non-cardiac causes include , a congenital blockage of the nasal passages that leads to cyclical cyanosis—worsening during feeding or quiet states and improving with due to —and deficiency in preterm infants, which contributes to respiratory distress and resultant hypoxia. In pediatric populations beyond the neonatal period, cyanosis may arise acutely from respiratory conditions such as severe exacerbations, where and ventilation-perfusion mismatch lead to , or , a common emergency in young children that can cause sudden choking, , and central cyanosis if the airway is obstructed. Perioral cyanosis, or circumoral cyanosis, refers to a bluish discoloration around the mouth and is particularly notable in young children, such as those around 4 years of age. Temporary and relatively harmless factors include hypothermia, prolonged crying, physical exertion, or exposure to cold, which typically resolve quickly after warming or calming the child. Serious conditions causing perioral cyanosis encompass respiratory problems such as asthma, pneumonia, or bronchiolitis; congenital heart defects; and dehydration, which can affect blood oxygenation and perfusion. Routine newborn screening via has become a for early detection of critical congenital heart disease (CCHD), a subset of cyanotic CHD; this non-invasive test, performed 24-48 hours after birth, identifies with a sensitivity of 70-90% for CCHD, significantly improving timely before discharge. Management of cyanosis in neonates and children requires age-specific considerations, including a lower threshold for intervention due to the neonate's higher concentration (typically 15-20 g/dL), which makes cyanosis visible at oxygen saturations above those in older children (around 85% versus 70-80%). For duct-dependent cyanotic lesions like transposition of the great arteries or , immediate infusion of (PGE1) is essential to maintain , ensuring adequate pulmonary or systemic blood flow until definitive surgical repair. Early intervention through screening and prompt treatment has dramatically improved outcomes; for instance, mandated screening reduces early from CCHD by 33%, averting approximately 120 deaths annually in the United States, while overall survival for untreated cyanotic CHD historically exceeded 50% mortality in the first year, now reduced to less than 10% with timely surgical and medical management.

Chronic and Comorbid Conditions

In patients with repaired cyanotic congenital heart disease, chronic cyanosis may persist due to residual shunts, pulmonary , or inadequate oxygenation from surgical palliation, leading to long-term hypoxia despite intervention. This persistence contributes to a high burden of chronic cardiac and noncardiac conditions, including arrhythmias and reduced exercise capacity, even decades post-repair. Similarly, , characterized by progressive fibrosis and impaired , frequently results in central cyanosis during advanced stages as alveolar hypoxia worsens. The body compensates for chronic hypoxia through physiological adaptations, notably an elevation in 2,3-diphosphoglycerate (2,3-DPG) levels, which binds to deoxyhemoglobin and induces a rightward shift in the oxyhemoglobin dissociation curve. This shift lowers hemoglobin's affinity for oxygen, enhancing tissue oxygen delivery despite reduced arterial saturation, a mechanism observed over weeks of sustained . Comorbidities often amplify cyanosis severity. , marked by daytime and nocturnal in obese individuals, commonly presents with cyanosis due to chronic respiratory insufficiency and cor pulmonale. exacerbates nocturnal desaturation in those with baseline cyanosis, such as from congenital heart disease, by causing intermittent airway obstruction and further drops in during sleep, independent of frank apnea events. In infection, associated pulmonary arterial hypertension promotes right ventricular strain and systemic hypoxia, culminating in cyanosis as disease progresses. In older adults, cyanosis—particularly manifesting as blue or purple discoloration of the lips—is frequently associated with chronic cardiopulmonary conditions such as chronic obstructive pulmonary disease (COPD) and congestive heart failure. Acute exacerbations of these conditions can lead to prominent cyanosis and often warrant prompt medical evaluation, especially when accompanied by symptoms such as shortness of breath, confusion, or chest pain. Chronic cyanosis triggers secondary as stimulates production to counter hypoxia, but this increases blood viscosity and elevates risk through and platelet activation. Additionally, the accelerated erythrocyte turnover in raises levels, predisposing patients to via hyperuricemia-induced crystal deposition in joints. Prolonged hypoxia also impairs neurodevelopment and cognition, with studies linking it to deficits in executive function, , and in affected children, likely from disrupted cerebral oxygenation and metabolic stress. Post-2020 advancements have enhanced of chronic cyanosis through telemedicine-enabled home oxygen monitoring, allowing real-time tracking to titrate and reduce hospital readmissions in hypoxemic patients. Congenital is a rare cause of persistent cyanosis due to b5 reductase deficiency.

Historical Development

Early Descriptions

The phenomenon of cyanosis, a bluish discoloration of the skin and mucous membranes due to deoxygenated , was noted in ancient texts. Descriptions of cyanopathia or Morbus caeruleus (cyanosis) have populated medical literature since the time of , although the actual remained poorly understood until much later. In the , William Harvey's seminal work Exercitatio Anatomica de Motu Cordis et Sanguinis in Animalibus (1628) advanced early insights into cyanosis by demonstrating the closed and noting how interruption of flow, such as through ligatures, led to tissue or discoloration distal to the obstruction, challenging Galenic views on movement and color differences between arteries and veins. This laid groundwork for linking skin color changes to circulatory dynamics rather than humoral imbalances alone. The 18th century saw more systematic descriptions. Jean-Baptiste de Senac, physician to King , provided the first pathophysiological explanation of cyanosis in his 1749 treatise Traité de la Structure du Coeur, de son Action, et de ses Maladies, proposing it resulted from mixing of arterial and in the heart, particularly in congenital defects. Concurrently, Leopold Auenbrugger's of chest percussion in 1761 (Inventum Novum ex Percussione Thoracis Humani) enabled better diagnosis of pulmonary conditions causing cyanosis, such as consolidation or in the lungs, by detecting abnormal sounds and dullness over affected areas. The term "cyanosis" derives from kyanos (dark blue) and entered medical lexicon in the early , with one of the earliest recorded uses in to describe the "blue disease" or blue jaundice observed in hypoxic states; it was sometimes confused with plethora (excess blood) before clearer distinctions emerged. In 1761, Morgagni further associated cyanosis with specific anatomical lesions like in his De Sedibus et Causis Morborum per Anatomen Indagatis. By the mid-19th century, Rudolf Virchow's revolutionary concept of cellular pathology (1858) connected cyanosis to microscopic tissue changes from hypoxia, emphasizing that disease manifestations like bluish discoloration arose from altered cellular function due to oxygen deprivation rather than gross organ failure alone. This shifted focus from descriptive observations to underlying mechanisms, bridging early anecdotal reports with emerging scientific pathology.

Modern Understanding

In the early 20th century, Danish physiologist provided foundational insights into oxygen transport by describing the sigmoidal oxyhemoglobin dissociation curve in 1904, which illustrated how 's affinity for oxygen varies with , influencing tissue oxygenation and the of cyanosis in hypoxic states. This curve explained the nonlinear binding of oxygen to , highlighting factors like and that shift the curve, thereby exacerbating desaturation in conditions leading to cyanosis. During the 1940s, pediatric cardiologist Helen Taussig advanced the understanding of shunt physiology in congenital heart disease, recognizing that reduced pulmonary blood flow caused severe cyanosis in infants with defects like . Taussig observed that persistent in some cyanotic children increased pulmonary flow and alleviated symptoms, inspiring the concept of surgical shunts to mimic this effect and reverse cyanosis by improving oxygenation. A key milestone was the 1944 Blalock-Taussig shunt procedure, which connected the to the , dramatically reducing cyanosis in affected infants and establishing palliative as a viable intervention for congenital cyanotic heart disease. Mid-20th-century innovations included the invention of in 1972 by Japanese engineer Takuo Aoyagi, who developed a noninvasive method using red and infrared light absorption ratios to measure arterial in real time, revolutionizing cyanosis detection by quantifying desaturation without blood sampling. By the , co-oximetry emerged as a critical tool for identifying dyshemoglobins like and , which cause pseudocyanosis by altering light absorption spectra; multiwavelength analyzers allowed precise quantification of these fractions, distinguishing true hypoxic cyanosis from dyshemoglobin-induced forms. In the late 20th and early 21st centuries, genetic research identified mutations in the cytochrome b5 reductase gene (CYB5R3) as causes of hereditary in the 1990s, with the first reported (S127P) in 1990 confirming enzyme deficiency as a molecular basis for chronic cyanosis unresponsive to . Studies also elucidated the effects of (HbF) in neonates, where its left-shifted dissociation curve maintains higher at low partial pressures, delaying visible cyanosis despite significant and complicating early diagnosis in newborns with congenital heart defects. Recent research has highlighted climate-related factors in high-altitude cyanosis among migrating populations, noting that warming temperatures and displacement to elevations above 2,500 meters exacerbate chronic hypoxia, , and cyanotic symptoms in non-adapted individuals due to reduced atmospheric oxygen and increased physiological stress. A pivotal advancement in neonatal care came with international guidelines in the endorsing screening for critical congenital heart disease, recommending measurements between 24 and 36 hours postbirth to detect cyanosis early, as adopted by bodies like the and endorsed globally to improve outcomes.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK559167/
  2. https://www.ncbi.nlm.nih.gov/books/NBK367/
  3. https://medlineplus.gov/ency/article/001104.htm
  4. https://www.npsg.uwaterloo.ca/resources/docs/cyanosis1.pdf
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC2598396/
  6. https://www.utmb.edu/pedi_ed/CoreV2/CardiologyPart1/CardiologyPart18.html
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC6069304/
  8. https://pubmed.ncbi.nlm.nih.gov/25161296/
  9. https://www.ncbi.nlm.nih.gov/books/NBK482316/
  10. https://pubmed.ncbi.nlm.nih.gov/18923862/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC3827510/
  12. https://www.ncbi.nlm.nih.gov/books/NBK500001/
  13. https://www.ncbi.nlm.nih.gov/books/NBK507800/
  14. https://www.ncbi.nlm.nih.gov/books/NBK526127/
  15. https://www.ncbi.nlm.nih.gov/books/NBK442011/
  16. https://www.ncbi.nlm.nih.gov/books/NBK537317/
  17. https://emedicine.medscape.com/article/204178-overview
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC2729224/
  19. https://pubmed.ncbi.nlm.nih.gov/15886294/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC6863029/
  21. https://pubmed.ncbi.nlm.nih.gov/33251782/
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC7536569/
  23. https://emedicine.medscape.com/article/303533-overview
  24. https://pubmed.ncbi.nlm.nih.gov/33401304/
  25. https://medlineplus.gov/ency/article/003394.htm
  26. https://public.iadvl.org/nail-care-basics
  27. https://www.ncbi.nlm.nih.gov/books/NBK557753/
  28. https://www.nhs.uk/symptoms/blue-skin-or-lips-cyanosis/
  29. https://my.clevelandclinic.org/health/diseases/24297-cyanosis
  30. https://www.healthline.com/health/circumoral-cyanosis
  31. https://my.clevelandclinic.org/health/diseases/22441-cyanotic-heart-disease
  32. https://www.osmosis.org/learn/Approach_to_cyanosis_%28newborn%29:_Clinical_sciences
  33. https://patient.info/doctor/history-examination/cyanosis
  34. https://journals.healio.com/doi/10.3928/00904481-20150203-12
  35. https://pedscases.com/sites/default/files/Approach%20to%20Cyanosis%20in%20a%20Neonate.pdf
  36. https://www.medicalnewstoday.com/articles/nail-health-chart
  37. https://www.ncbi.nlm.nih.gov/books/NBK593199/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC5531304/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC6514285/
  40. https://www.ncbi.nlm.nih.gov/books/NBK544260/
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC9291883/
  42. https://emcrit.org/ibcc/shock/
  43. https://pubmed.ncbi.nlm.nih.gov/39385596/
  44. https://pubmed.ncbi.nlm.nih.gov/33140712/
  45. https://www.ncbi.nlm.nih.gov/books/NBK551631/
  46. https://www.mayoclinic.org/diseases-conditions/pulmonary-embolism/diagnosis-treatment/drc-20354653
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC10289616/
  48. https://www.ncbi.nlm.nih.gov/books/NBK470315/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC11266082/
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC8215527/
  51. https://publications.aap.org/neoreviews/article/25/7/e443/197559/Persistent-Cyanosis-in-a-Newborn
  52. https://www.cdc.gov/heart-defects/data/index.html
  53. https://www.ncbi.nlm.nih.gov/books/NBK507724/
  54. https://publications.aap.org/pediatriccare/article/doi/10.1542/aap.ppcqr.396461/172/Cyanosis
  55. https://publications.aap.org/aapbooks/book/676/chapter/8138028/Foreign-Body-Aspiration
  56. https://www.aafp.org/pubs/afp/issues/2019/0401/p421.html
  57. https://www.safercare.vic.gov.au/best-practice-improvement/clinical-guidance/neonatal/cyanosed-neonate-assessment
  58. https://www.cdc.gov/heart-defects/hcp/screening/index.html
  59. https://www.jacc.org/doi/10.1016/j.jacadv.2025.101775
  60. https://www.ahajournals.org/doi/10.1161/JAHA.119.015354
  61. https://www.mayoclinic.org/diseases-conditions/interstitial-lung-disease/symptoms-causes/syc-20353108
  62. https://www.ncbi.nlm.nih.gov/books/NBK499818/
  63. https://medlineplus.gov/ency/article/000085.htm
  64. https://pubmed.ncbi.nlm.nih.gov/17643525/
  65. https://www.ahajournals.org/doi/10.1161/circulationaha.114.006978
  66. https://my.clevelandclinic.org/health/symptoms/24905-cyanosis
  67. https://www.sciencedirect.com/science/article/abs/pii/S1058981319301146
  68. https://www.mayoclinic.org/diseases-conditions/polycythemia-vera/symptoms-causes/syc-20355850
  69. https://publications.aap.org/pediatrics/article/114/3/805/67165/The-Effect-of-Chronic-or-Intermittent-Hypoxia-on
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC9803390/
  71. https://amjmed.org/cyanosis/
  72. https://www.sciencedirect.com/science/article/pii/S1538783622055179
  73. https://litfl.com/leopold-auenbrugger/
  74. https://www.etymonline.com/word/cyanosis
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC2603088/
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC12264582/
  77. https://www.sciencedirect.com/science/article/abs/pii/S1095643320302336
  78. https://www.acc.org/Latest-in-Cardiology/Articles/2020/03/01/08/42/Feature-Pediatric-Cardiology-A-Specialty-Spurred-by-the-Groundbreaking-Work-of-Women-The-Legacies-of-Maude-Abbott-MD-and-Helen-B-Taussig-MD-FACC
  79. https://www.heart.org/en/news/2024/03/28/dr-helen-taussigs-work-saved-blue-babies
  80. https://www.jtcvs.org/article/S0022-5223%2810%2900682-3/fulltext
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC8327306/
  82. https://acutecaretesting.org/en/articles/to-coox-or-not-to-coox
  83. https://www.sciencedirect.com/science/article/abs/pii/S1079979605001531
  84. https://journals.physiology.org/doi/10.1152/physiol.00029.2021
  85. https://www.ahajournals.org/doi/10.1161/circulationaha.109.192576
Add your contribution
Related Hubs
Contribute something
User Avatar
No comments yet.